The cost effectiveness of two new antiepileptic therapies in the absence of direct comparative data: A first approximation

PharmacoEconomics

Volumn 21, Issue 5, 2003, Pages 315-326

  Van Hout, Ben A ^a,b   Gagnon, Dennis D ^c   McNulty, Pauline ^c   O'Hagan, Anthony ^d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b PharMerit ^*  (Netherlands)

^c ICOM Health Economics   (United States)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; LAMOTRIGINE; PLACEBO; TOPIRAMATE; DRUG DERIVATIVE; FRUCTOSE; TRIAZINE DERIVATIVE;

ANTICONVULSANT THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; EPILEPSY; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; BAYES THEOREM; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS;

ANTICONVULSANTS; BAYES THEOREM; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; EPILEPSY; FRUCTOSE; HUMANS; MODELS, ECONOMIC; TRIAZINES;

EID: 0037251263     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200321050-00003     Document Type: Article

References (43)

1. Marson AG, Kadit ZA, Hutton JL, et al. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997; 38 (8): 859-80
2. Ramaratnam S, Marson AG, Baker GA. Lamotrigine add-on for drug-resistant partial epilepsy. Available from The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 3. Oxford: Update Software, 2001: CD001909
3. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998; 18 Suppl. 2: S68-80
4. Cooper H, Hedges LV, editors. The handbook of research synthesis. New York: Russel Sage Foundation, 1994
5. Guberman A, Neto W, Gassmann-Mayer C, the EPAJ-119 Study Group. Low-dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurol Scand 2002; 106 (4); 183-9
6. Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 1991; 10: 1677
7. Sachdeo R, Kramer LD, Rosenberg A, et al. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol 1992; 32 (3): 386-92
8. Chiron C, Dumas C, Dulac O. Vigabatrin versus hydrocortisone as first-line monotherapy in infantile spasms due to tuberous sclerosis. Epilepsia 1995; 36 Suppl. 3: S265
9. Spilker B, Segreti A. Validation of the phenomenon of regression of seizure frequency in epilepsy. Epilepsia 1984; 25 (4): 443-9
10. Willmore JL. Depakote adjunctive therapy in the treatment of partial seizures. Epilepsia 1995; 36 Suppl. 3: S66
11. Pocock SJ. Clinical trials: a practical approach. New York: John Wiley, 1983
12. Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed eplepsy. Lancet 1995; 345 (8948): 476-9
13. Binnie CD, Debets RM, Engelsman M, et al. Double blind cross-over trial of lamotrigine (Lamictal) as add on therapy in intractable epilepsy. Epilepsy Res 1989; 4 (3): 222-9
14. Boas J, Dam M, Friis ML, et al. Controlled trial of lamotrigine (Lamictal®) for treatment-resistant partial seizures. Acta Neurol Scand 1996; 94: 247-52
15. Jawad S, Richens A, Goodwin G, et al. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia 1989; 30 (3): 356-63
16. Loiseau P, Yuen AW, Duche B, et al. A randomised double blind placebo controlled cross-over add on trial of lamotrigine in patients with treatment resistant partial seizures. Epilepsy Res 1990; 7 (2): 136-45
17. Messenheimer J, Ramsey RE, Willmore LJ, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 1994; 35 (1): 113-21
18. Schapel GJ, Beran RG, Vajda FJ, et al. Double blind, placebo controlled, cross-over study of lamotrigine in treatment resistant partial seizures. J Neurol Neurosurg Psychiatry 1993; 56 (5): 448-53
19. Schmidt D, Jacob R, Loiseau P. Zonisamide for add on treatment of refractory partial epilepsy: a European double blind trial. Epilepsy Res 1993; 15 (1): 67-73
20. Smith D, Baker G, Davies G, et al. Outcomes of add on treatment with lamotrigine in partial epilepsy. Epilepsia 1993; 34 (2): 312-22
21. Matsuo F, Bergen D. Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures: U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology 1993; 43 (11): 2284-91
22. Elterman RD, Glauser TA, Wyllie E, et al. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children: Topiramate YP Study Group. Neurology 1999; 52: 1338-44
23. Sachdeo RC, Glauser TA, Ritter F, et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome: Topiramate YL Study Group. Neurology 1999; 52: 1882-7
24. Reife R, Pledger G, Wu SC. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 2000; 41 Suppl. 1: S66-71
25. Kamin M, Kraut L, Olson WH. Tolerability and safety of topiramate (TPM) in a community based study (TRAITS) of adults with partial-onset seizures [abstract]. Epilepsia 1999; 40 Suppl. 7: 5
26. Pellock J, Kamin M, Kraut L, et al. Adverse events (AEs) when topiramate is titrated to effect: results from an open-label, in-practice study with 800+ patients [abstract]. Epilepsia 2000; 41 Suppl. 7: 105
27. Chadwick DW, Marson T, Kadir Z. Clinical administration of new antiepileptic drugs: an overview of safety and efficacy. Epilepsia 1996; 37 Suppl. 6: S17-22
28. Jette NJ, Marson AG, Kadir ZA, et al. Topiramate for drug-resistant partial epilepsy. Available from The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 3. Oxford: Update Software, 2001: CD001417
29. Sander JW. Practical aspects of the use of topiramate in patients with epilepsy. Epilepsia 1997; 38 Suppl. 1: S56-8
30. Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996; 37 Suppl. 2: S18-22
31. Peeters K, Adrianssen I, Wapenaar R, et al. A pooled analysis of adjunctive topiramate in refractory partial epilepsy. Acta Neurol Scand. In press
32. Begley CE, Lairson DR, Reynolds TF, et al. Early treatment cost in epilepsy and how it varies with seizure type and frequency. Epilepsy Res 2001; 47: 205-15
33. de Zelicourt M, Bureau L, Fagnani F, et al. The contributing factors to medical cost of epilepsy: an estimation based on a French prospective cohort study of patients with newly diagnosed epileptic seizures (the CAROLE study). Seizure 2000; 9: 88-95
34. Jacoby A, Buck D, Baker G, et al. Uptake and costs of care for epilepsy: findings from a UK regional study. Epilepsia 1998: 39 Suppl. 7: 776-86
35. Van Hout BA, Gagnon D, McNulty P. An economic evaluation of topiramate versus placebo, gabapentin, and lamotrigine [abstract]. Neurology 1997; 48 Suppl. 3: A170
36. Van Hout B, Gagnon D, Souetre E, et al. Relationship between seizure frequency and costs and quality of life of outpatients with partial epilepsy in France, Germany, and the United Kingdom. Epilepsia 1997; 38: 1221-6
37. Haymarket Medical Ltd. eMIMS: the definitive prescribing information system [onlinel. Available from URL: http://www.emims.net [Accessed 2001 Oct 15]
38. Grieve AP. Issues for statisticians in pharmaco-economic evaluations. Stat Med 1998; 17: 1715-23
39. O'Hagan A, Stevens JW, Montmartin J. Inference for the costeffectiveness acceptability curve and cost-effectiveness ratio. Pharmacoeconomics 2000; 17 (4): 339-49
40. Jones DA. A Bayesian approach to the economic evaluation of health care technologies. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia (PA): Lippincott-Raven, 1996: 1189-96
41. Lilford RJ, Braunholtz D. The statistical basis of public policy: a paradigm shift is overdue. BMJ 1996; 313: 603-7
42. Lilford RJ, Braunholtz D. Who's afraid of Thomas Bayes? J Epidemiol Community Health 2000; 54 (10): 731-9
43. Spiegelhalter DJ, Abrams K, Myles JP. Bayesian approaches to clinical trials and healthcare evaluation. Wiley. In press